文献速递前列腺增生与排尿功能障碍

Aquablation治疗30-80mL与80-150mL前列腺的WATER与WATER II试验比较

Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30-80 and 80-150 mL prostates.
PubMed 文献 · BJU Int · 2019-11-08

两项前瞻性国际试验比较Aquablation治疗30-80mL(WATER,n=116)与80-150mL(WATER II,n=101)前列腺增生患者12个月结局。两组IPSS平均改善分别为15.1和17.1(P=0.605),3个月内Clavien-Dindo≥II级事件发生率分别为19.8%和34.7%(P=0.468)。结论认为Aquablation可使不同体积前列腺获得临床可比的结果,但大体积并发症风险预期增加。

要点

  • Aquablation在30-80mL与80-150mL前列腺中12个月IPSS改善无显著差异(P=0.605)。
  • 大体积(80-150mL)患者3个月内Clavien-Dindo≥II级事件发生率数值更高(34.7% vs 19.8%,P=0.468)。
  • 实际治疗时间W-I为4分钟、W-II为8分钟,手术时间分别为33和37分钟。

核心结论

  • Aquablation可使30-80mL与80-150mL前列腺增生患者在12个月时获得临床可比的功能改善,但大体积前列腺并发症风险预期增加。
  • 研究提示Aquablation的疗效在不同前列腺体积间具有可重复性。

研究设计与样本

  • WATER(W-I;NCT02505919)为前瞻性、双盲、多中心、国际临床试验,比较Aquablation与经尿道前列腺电切术(TURP)治疗30-80mL前列腺的LUTS/BPH。
  • WATER II(W-II;NCT03123250)为前瞻性、多中心、单臂国际临床试验,评估Aquablation治疗80-150mL前列腺。
  • 比较W-I的116例与W-II的101例患者基线参数及12个月结局。

主要发现

  • 平均(SD)手术时间W-I为33(17)分钟,W-II为37(13)分钟。
  • 实际治疗时间W-I为4分钟,W-II为8分钟。
  • 12个月时国际前列腺症状评分(IPSS)平均变化W-I为15.1,W-II为17.1(P=0.605)。
  • 3个月时Clavien-Dindo≥II级事件发生率W-I为19.8%,W-II为34.7%(P=0.468)。

关键数值与推荐

  • W-I纳入前列腺体积30-80mL,W-II纳入80-150mL。
  • IPSS平均变化12个月时W-I为15.1、W-II为17.1,组间P=0.605。
  • Clavien-Dindo≥II级事件3个月内W-I为19.8%、W-II为34.7%,组间P=0.468。

临床怎么用

  • Aquablation可用于30-80mL及80-150mL前列腺的LUTS/BPH治疗,大体积患者需预期更高的并发症风险。
  • 临床决策时应结合前列腺体积评估Aquablation的获益与风险。

局限性

  • W-II为单臂试验,非随机对照比较。
  • 需要长期结局评估手术持久性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the outcomes of Aquablation in 30-80 mL prostates with those in 80-150 mL prostates. Surgical options, especially with short learning curves, are limited when treating large prostates for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Aquablation (AquaBeam System, PROCEPT BioRobotics Inc., Redwood City, CA, USA) could solve this issue with global reproducibility, independent of prostate volume. PATIENTS AND METHODS: Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue (WATER [W-I]; NCT02505919) is a prospective, double-blind, multicentre, international clinical trial comparing Aquablation and transurethral resection of the prostate (TURP) for the treatment of LUTS/BPH in prostates between 30 and 80 mL. WATER II (W-II; NCT03123250) is a prospective, multicentre, single-arm international clinical trial of Aquablation in prostates between 80 and 150 mL. We compare baseline parameters and 12-month outcomes in 116 W-I and 101 W-II study patients. Students' t-test or Wilcoxon tests were used for continuous variables and Fisher's test for binary variables. RESULTS: The mean (SD) operative time was 33 (17) and 37 (13) min in W-I and W-II, respectively. Actual treatment time was 4 and 8 min in W-I and W-II, respectively. The mean change in the International Prostate Symptom Score was substantial averaging (at 12 months) 15.1 in W-I and 17.1 in W-II (P = 0.605). By 3 months, Clavien-Dindo grade ≥II events occurred in 19.8% of W-I patients and 34.7% of W-II patients (P = 0.468). CONCLUSION: Aquablation clinically normalises outcomes between patients with 30-80 mL prostates and patients with 80-150 mL prostates treated for LUTS/BPH, with an expected increase in the risk of complications in larger prostates. Long-term outcomes of procedure durability are needed.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Nguyen DD, Barber N, Bidair M, et al. Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30-80 and 80-150 mL prostates. BJU Int. 2019. PMID: 31599044. doi:10.1111/bju.14917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。